Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release

European Journal of Neuroscience

Volumn 29, Issue 3, 2009, Pages 529-538

  Zmarowski, A ^a   Wu, H Q ^b   Brooks, J M ^a   Potter, M C ^b   Pellicciari, R ^c   Schwarcz, R ^b   Bruno, J P ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Amphetamine; Glia; Microdialysis; Prefrontal cortex; Schizophrenia

Indexed keywords

ACETYLCHOLINE; ALANINE DERIVATIVE; DEXAMPHETAMINE; KYNURENIC ACID; KYNURENINE; S ETHYLSULFONYLBENZOYLALANINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ATTENUATION; BRAIN CORTEX; BRAIN FUNCTION; BRAIN LEVEL; CATALYSIS; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; CONTROLLED STUDY; MALE; MODULATION; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ACETYLCHOLINE; AMPHETAMINE; ANIMALS; ASTROCYTES; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; ENZYME INHIBITORS; KYNURENIC ACID; MALE; NICOTINIC ANTAGONISTS; PREFRONTAL CORTEX; PRESYNAPTIC TERMINALS; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; TRANSAMINASES; UP-REGULATION;

EID: 59149100167     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2008.06594.x     Document Type: Article

References (78)

1. Alkondon, M., Pereira, E.F., Eisenberg, H.M. Albuquerque, E.X. (2000) Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J. Neurosci., 20, 66 75.
2. Alkondon, M., Pereira, E.F., Yu, P., Arruda, E.Z., Almeida, L.E., Guidetti, P., Fawcett, W.P., Sapko, M.T., Randall, W.R., Schwarcz, R., Tagle, D.A. Albuquerque, E.X. (2004) Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J. Neurosci., 24, 4635 4648.
3. Amtage, F., Neughebauer, B., McIntosh, J.M., Freiman, T., Zentner, J., Feuerstein, T.J. Jackisch, R. (2004) Characterization of nicotinic receptors inducing noradrenaline release and absence of nicotinic autoreceptors in human neocortex. Brain Res. Bull., 62, 413 423.
4. Arnold, H.M., Nelson, C.L., Neigh, G.N., Sarter, M. Bruno, J.P. (2000) Systemic and intra-accumbens administration of amphetamine differentially affects cortical acetylcholine release. Neuroscience, 96, 675 685.
5. Bergeron, R., Wu, H.-Q., Potter, M.C., Guidetti, P. Schwarcz, R. (2007) Mice with reduced brain kynurenic acid levels have high extracellular glutamate and show enhanced LTP in the hippocampus. Soc. Neurosci. Abstr., 32, 807.15.
6. Boyer, P., Phillips, J.L., Rousseau, F.L. Ilivitsky, S. (2007) Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. Brain Res. Rev., 54, 92 112.
7. Brooks, J.M., Sarter, M. Bruno, J.P. (2007) D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex. Neuropharmacology, 53, 455 463.
8. Bruno, J.P., Sarter, M., Arnold, H.M. Himmelheber, A.M. (1999) In vivo neurochemical markers of cognitive processes: methodological and conceptual challenges. Rev. Neurosci., 10, 25 49.
9. Buchanan, R.W., Conley, R.R., Dickinson, D., Ball, M.P., Feldman, S., Gold, J.M. McMahon, R.P. (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry, 165, 82 89.
10. Cao, Y.J., Surowy, C.S. Puttfarcken, P.S. (2005) Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release. Neuropharmacology, 48, 72 79.
11. Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri, M. Moroni, F. (2001) Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci., 13, 2141 2147.
12. Ceresoli-Borroni, G., Rassoulpour, A., Wu, H.Q., Guidetti, P. Schwarcz, R. (2006) Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J. Neural Transm., 113, 1355 1365.
13. Chess, A.C. Bucci, D.J. (2006) Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav. Brain Res., 170, 326 332.
14. Coyle, J.T. (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol., 26, 365 384.
15. Dani, J.A. Bertrand, D. (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol., 47, 699 729.
16. Del Arco, A. Mora, F. (2005) Glutamate-dopamine in vivo interaction in the prefrontal cortex modulates the release of dopamine and acetylcholine in the nucleus accumbens of the awake rat. J. Neural Transm., 112, 97 109.
17. Del Arco, A., Mora, F., Mohammed, A.H. Fuxe, K. (2007) Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens. J. Neural Transm., 114, 185 193.
18. Dickinson, J.A., Kew, J.N. Wonnacott, S. (2008) Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol. Pharmacol., 74, 348 359.
19. Du, F., Schmidt, W., Okuno, E., Kido, R., Köhler, C. Schwarcz, R. (1992) Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J. Comp. Neurol., 321, 477 487.
20. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L.H. Engberg, G. (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett., 313, 96 98.
21. Erhardt, S., Schwieler, L., Emanuelsson, C. Geyer, M. (2004) Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry, 56, 255 260.
22. Fadel, J., Sarter, M. Bruno, J.P. (2001) Basal forebrain glutamatergic modulation of cortical acetylcholine release. Synapse, 39, 201 212.
23. Feuerbach, D., Lingenhoehl, K., Olpe, H.R., Vassout, A., Gentsch, C., Chaperon, F., Nozulak, J., Enz, A., Bilbe, G., McAllister, K. Hoyer, D. (2008) The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 2008 Aug 28 (published ahead of print).
24. Gioanni, Y., Rougeot, C., Clarke, P.B., Lepousé, C., Thierry, A.M. Vidal, C. (1999) Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur. J. Neurosci., 11, 18 30.
25. Giovannini, M.G., Giovannelli, L., Bianchi, L., Kalfin, R. Pepeu, G. (1997) Glutamatergic modulation of cortical acetylcholine release in the rat: a combined in vivo microdialysis, retrograde tracing and immunohistochemical study. Eur. J. Neurosci., 9, 1678 1689.
26. Grilli, M., Raiteri, L., Patti, L., Parodi, M., Robino, F., Raiteri, M. Marchi, M. (2006) Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain. Br. J. Pharmacol., 149, 724 732.
27. Guan, Z.Z., Zhang, X., Blennow, K. Nordberg, A. (1999) Decreased protein level of nicotinic alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport, 10, 1779 1782.
28. Guidetti, P., Amori, L., Sapko, M.T., Okuno, E. Schwarcz, R. (2007a) Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem., 102, 103 111.
29. Guidetti, P., Hoffman, G.E., Melendez-Ferro, M., Albuquerque, E.X. Schwarcz, R. (2007b) Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia, 55, 78 92.
30. Hasselmo, M.E. Stern, C.E. (2006) Mechanisms underlying working memory for novel information. Trends Cogn. Sci., 10, 487 493.
31. Hilmas, C., Pereira, E.F., Alkondon, M., Rassoulpour, A., Schwarcz, R. Albuquerque, E.X. (2001) The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J. Neurosci., 21, 7463 7473.
32. Höcht, C., Opezzo, J.A. Taira, C.A. (2007) Applicability of reverse microdialysis in pharmacological and toxicological studies. J. Pharmacol. Toxicol. Methods., 55, 3 15.
33. Hyde, T.M. Crook, J.M. (2001) Cholinergic systems and schizophrenia: primary pathology or epiphenomena J. Chem. Neuroanat., 22, 53 63.
34. Keefe, R.S. (2007) Cognitive deficits in patients with schizophrenia: effects and treatments. J. Clin. Psychiatry, 68, (Suppl. 14), 8 13 Barch, D.M. (2008) Executive functioning component mechanisms and schizophrenia. Biol. Psychiatry, 64, 26 33.
35. Koike, K., Hashimoto, K., Takai, N., Shimizu, E., Komatsu, N., Watanabe, H., Nakazato, M., Okamura, N., Stevens, K.E., Freedman, R. Iyo, M. (2005) Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr. Res., 76, 67 72.
36. Kozak, R., Martinez, V., Young, D., Brown, H., Bruno, J.P. Sarter, M. (2007) Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacology, 32, 2074 2086.
37. Krystal, J.H., D'Souza, D.C., Mathalon, D., Perry, E., Belger, A. Hoffman, R. (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology, 169, 215 233.
38. Laruelle, M., Kegeles, L.S. Abi-Dargham, A. (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. NY Acad. Sci., 1003, 135 158.
39. Leonard, S. Freedman, R. (2006) Genetics of chromosome 15q13-q14 in schizophrenia. Biol. Psychiatry, 60, 115 122.
40. Lewis, D.A. Moghaddam, B. (2006) Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol., 63, 1372 1376.
41. Lewis, D.A., Hashimoto, T. Volk, D.W. (2005) Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci., 6, 312 324.
42. Linderholm, K.R., Andersson, A., Olsson, S., Olsson, E., Snodgrass, R., Engberg, G. Erhardt, S. (2007) Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology, 53, 918 924.
43. Lopes, C., Pereira, E.F.R., Wu, H.-Q., Purushottamachar, P., Njar, V., Schwarcz, R. Albuquerque, E.X. (2007) Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at α7* nicotinic receptors. J. Pharmacol. Exp. Ther., 322, 48 58.
44. Luccini, E., Musante, V., Neri, E., Raiteri, M. Pittaluga, A. (2007) N-Methyl-D-aspartate autoreceptors respond to low and high agonist concentrations by facilitating, respectively, exocytosis and carrier-mediated release of glutamate in rat hippocampus. J. Neurosci. Res., 85, 3657 3665.
45. Marchi, M., Risso, F., Viola, C., Cavazzani, P. Raiteri, M. (2002) Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem., 80, 1071 1078.
46. Martin, L.F., Kem, W.R. Freedman, R. (2004) Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology, 174, 54 64.
47. Martin, K.F., Leonard, S., Hall, M.H., Tregelias, J.R., Freedman, R. Olincy, A. (2007) Sensory gating and alpha7-nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am. J. Med. Genet. B Neuropsychiatr. Genet., 144B, 611 614.
48. Mattay, V.S., Callicott, J.H., Bertolino, A., Heaton, I., Frank, J.A., Coppola, R., Berman, K.F., Goldberg, T.E. Weinberger, D.R. (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage, 12, 268 275.
49. Moghaddam, B. (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron, 40, 881 884.
50. Nelson, C.L., Sarter, M. Bruno, J.P. (2005) Prefrontal cortical modulation of acetylcholine release in posterior parietal cortex. Neuroscience, 132, 347 359.
51. Olincy, A. Stevens, K.E. (2007) Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men. Biochem. Pharmacol., 74, 1192 1201.
52. Olincy, A., Harris, J.G., Johnson, L.L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G.O., Leonard, S., Stevens, K.E., Stevens, J.O., Martin, L., Adler, L.E., Soti, F., Kerm, W.R. Freeman, R. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry, 63, 630 638.
53. Parikh, V., Man, K., Decker, M.W. Sarter, M. (2008) Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J. Neurosci., 28, 3769 3780.
54. Pellicciari, R., Rizzo, R., Costantino, G., Marinozzi, M., Amori, L., Guidetti, P., Wu, H.-Q. Schwarcz, R. (2006) Modulators of the kynurenine pathway of tryptophan metabolism. Synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem., 1, 528 531.
55. Perkins, M.N. Stone, T.W. (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res., 247, 184 187.
56. Pichat, P., Bergis, O.E., Terranova, J.P., Urani, A., Duarte, C., Santucci, V., Gueudet, C., Voltz, C., Steinberg, R., Stemmelin, J., Oury-Donat, F., Avenet, P., Griebel, G. Scatton, B. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology, 32, 17 34.
57. Potter, P.E., Meek, J.L. Neff, N.H. (1983) Acetylcholine and choline in neuronal tissue measured by HPLC with electrochemical detection. J. Neurochem., 41, 188 194.
58. Potter, M.C., Elmer, G.I., Guidetti, P., Calu, D. Schwarcz, R. (2006) Improved behavioral performance of kynurenine aminotransferase II-deficient mice in hippocampus-based learning and memory paradigms. Soc. Neurosci. Abstr., 32, 265.9.
59. Rassoulpour, A., Wu, H.-Q., Poeggeler, B. Schwarcz, R. (1998) Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain. Brain Res., 802, 111 118.
60. Rassoulpour, A., Wu, H.-Q., Ferré, S. Schwarcz, R. (2005) Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem., 93, 762 765.
61. 3H]-D-aspartate release from rat frontal cortex in vitro. Neuropharmacology, 49, 59 72.
62. Sarter, M., Nelson, C.L. Bruno, J.P. (2005) Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr. Bull., 31, 117 138.
63. Sathyasaikumar, K.V., Rassoulpour, A., Stachowski, E., Guidetti, P., Roberts, R.C. Schwarcz, R. (2008) Impaired cortical kynurenine pathway metabolism in schizophrenia. Soc. Neurosci. Abstr., 33, 54.20.
64. Schubert, M.H., Young, K.A. Hicks, P.B. (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry, 60, 530 533.
65. Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C.A. Roberts, R.C. (2001) Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry, 50, 521 530.
66. Severance, E.G. Yolken, R.H. (2008) Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav., 7, 37 45.
67. Shearman, E., Rossi, S., Sershen, H., Hashim, A. Lajtha, A. (2005) Locally administered low nicotine-induced neurotransmitter changes in areas of cognitive function. Neurochem. Res., 30, 1055 1066.
68. Shepard, P.D., Joy, B., Clerkin, L. Schwarcz, R. (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology, 28, 1454 1462.
69. Swartz, K., During, M.J., Freese, A. Beal, M.F. (1990) Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci., 10, 2965 2973.
70. Tan, H.Y., Callicott, J.H. Weinberger, D.R. (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb. Cortex., 17 (Suppl. 1 171 181.
71. Toda, M. Abi-Dargham, A. (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr. Psychiatry. Rep., 9, 329 336.
72. Turski, W.A., Gramsbergen, J.B.P., Traitler, H. Schwarcz, R. (1989) Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J. Neurochem., 52, 1629 1636.
73. Vasey, M.W. Thayer, J.F. (1987) The continuing problem of false positives in repeated measures ANOVA in psychophysiology: a multivariate solution. Psychophysiology, 24, 479 486.
74. Wu, H.-Q., Pellicciari, R. Schwarcz, R. (2006) Bidirectional regulation of extracellular dopamine by endogenous kynurenic acid in the rat medial prefrontal cortex. Soc. Neurosci. Abstr., 32, 624.3.
75. Wu, H.-Q., Pellicciari, R., Bruno, J.P. Schwarcz, R. (2008) Endogenous kynurenate modulates extracellular glutamate levels in the rat medial prefrontal cortex. Soc. Neurosci. Abstr., 34, 657.50.
76. Yang, C.R. Chen, L. (2005) Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment. Neuroscientist, 11, 452 470.
77. Zmarowski, A., Sarter, M. Bruno, J.P. (2005) NMDA and dopamine interactions in the nucleus accumbens modulate cortical acetylcholine release. Eur. J. Neurosci., 22, 1731 1740.
78. Zmarowski, A., Sarter, M. Bruno, J.P. (2007) Glutamate receptors in nucleus accumbens mediate regionally selective increases in cortical acetylcholine release. Synapse, 61, 115 123.